title: RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
abstract: Although the biological factors that contribute to the pathogenesis of chronic lymphocytic leukemia (CLL) remain widely unresolved, it has been suggested that dysregulated cell survival and proliferation are fundamental to this process. Constitutive classical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation protects CLL B-cells from cell death and plays a critical role in the acquisition of chemoresistance. RelB, representing the alternative NF-κB activity, functions specifically in lymphoid organogenesis and B-cell maturation. RelB indeed plays a tumor-supportive role and confers radiation resistance in tumors. However, the involvement of RelB in CLL has not been addressed. Here, we analyzed the NF-κB activation in 67 of CLL bone marrow (BM). Both the RelA and RelB activity were detected in CLL B-cells from BM, in spite of inevitable variability. Low RelB activity was linked to a favorable prognosis of CLL. The migration and adhesion abilities of CLL B-cells were not affected by the RelB activity. High RelB activity, together with the RelA activity, maintained basal survival of cells. The induction of RelA and RelB expression in the nucleus was responsible for better survival of CLL B-cells supported by bone marrow stromal cells. In addition, the presence of high RelB activity in CLL B-cells was correlated with sensitivity to proteasome inhibitor but not fludarabine. Taken together, we provided evidences that not only RelA but also RelB, subunits of NF-κB family, played an important role in the cellular behaviors of CLL cells from BM. The strength of RelB activity influenced the prognosis of CLL patients.
  
  
  CONCLUSIONS
  RelB, with RelA activity, maintained the basal survival of CLL cells from BM. RelB, with RelA, conferred the proteasome inhibitor sensitivity of CLL cells. Induction of RelA and RelB was responsible for the better survival of CLL B-cells. The strength of RelB activity influenced the prognosis of CLL patients.
authors.affiliation: Central Lab, The First Affiliated Hospital of Soochow University, Shizi Road 188, Suzhou, China, 215006.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Xu
authors.forename: Peng
authors.initials: P
authors.lastname: Zhou
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Wang
authors.forename: Aining
authors.initials: A
authors.lastname: Sun
authors.forename: Feng
authors.initials: F
authors.lastname: Guo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D002869:Chromosome Aberrations; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004789:Enzyme Activation; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D059630:Mesenchymal Stem Cells / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D009154:Mutation; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D009367:Neoplasm Staging; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D051881:Receptor, Notch1 / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*; D051841:Transcription Factor RelB / Q000235:genetics / Q000378:metabolism*
chemical_list: D018925:Chemokines; D007143:Immunoglobulin Heavy Chains; D016328:NF-kappa B; D061988:Proteasome Inhibitors; D051881:Receptor, Notch1; D051996:Transcription Factor RelA; D051841:Transcription Factor RelB
references.citation: Br J Haematol. 2012 Apr;157(1):59-66
references.pmid: 22171982
references.citation: Br J Haematol. 1996 Jan;92(1):97-103
references.pmid: 8562418
references.citation: Blood. 2011 Jan 13;117(2):563-74
references.pmid: 20940416
references.citation: Blood. 1999 Dec 1;94(11):3658-67
references.pmid: 10572077
references.citation: Blood. 2012 Jan 12;119(2):521-9
references.pmid: 22077063
references.citation: Blood. 1998 Aug 1;92(3):990-5
references.pmid: 9680368
references.citation: Blood. 2010 Apr 29;115(17):3541-52
references.pmid: 20053756
references.citation: Oncogene. 2007 Feb 22;26(8):1166-77
references.pmid: 16924235
references.citation: Mol Immunol. 2009 Aug;46(13):2441-8
references.pmid: 19540595
references.citation: Leukemia. 2011 May;25(5):828-37
references.pmid: 21372840
references.citation: J Immunol. 2012 Jun 15;188(12):6071-83
references.pmid: 22593611
references.citation: Nat Cell Biol. 2007 Apr;9(4):470-8
references.pmid: 17369819
references.citation: Cancer Res. 2009 Apr 15;69(8):3267-71
references.pmid: 19351823
references.citation: Leukemia. 2004 Aug;18(8):1391-400
references.pmid: 15175625
references.citation: Blood. 1998 Apr 1;91(7):2387-96
references.pmid: 9516138
references.citation: Mol Cell Biol. 2009 Jul;29(14):3832-44
references.pmid: 19433448
references.citation: Leuk Res. 2007 Jul;31(7):899-906
references.pmid: 17241660
references.citation: J Clin Oncol. 2009 Feb 10;27(5):763-9
references.pmid: 19124804
references.citation: Ann N Y Acad Sci. 2010 Jul;1201:129-36
references.pmid: 20649549
references.citation: Leukemia. 2008 Sep;22(9):1712-20
references.pmid: 18596739
references.citation: Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2874-9
references.pmid: 15708970
references.citation: J Clin Invest. 2005 Mar;115(3):755-64
references.pmid: 15711642
references.citation: Blood. 2007 Jan 15;109(2):703-10
references.pmid: 16973958
references.citation: Annu Rev Immunol. 2009;27:693-733
references.pmid: 19302050
references.citation: Blood. 2012 Nov 1;120(18):3756-63
references.pmid: 22968463
references.citation: Blood. 2011 Feb 10;117(6):1781-91
references.pmid: 21148333
references.citation: Immunol Rev. 2003 Oct;195:91-105
references.pmid: 12969313
references.citation: Leukemia. 2013 Apr;27(5):1100-6
references.pmid: 23295735
references.citation: Expert Opin Ther Targets. 2010 Mar;14(3):275-88
references.pmid: 20148715
references.citation: Blood. 2009 May 7;113(19):4481-2
references.pmid: 19423738
references.citation: J Natl Cancer Inst. 2007 Sep 19;99(18):1362-4
references.pmid: 17848662
references.citation: Blood. 2012 Mar 22;119(12):2854-62
references.pmid: 22308293
references.citation: Leukemia. 2007 Jul;21(7):1521-31
references.pmid: 17476277
references.citation: Br J Haematol. 2009 Nov;147(4):471-83
references.pmid: 19751240
references.citation: Mol Immunol. 2011 Oct;49(1-2):8-17
references.pmid: 21856005
references.citation: Nature. 2011 Jun 05;475(7354):101-5
references.pmid: 21642962
references.citation: Blood. 2008 Aug 1;112(3):551-9
references.pmid: 18505785
references.citation: Cancer. 2006 Sep 1;107(5):916-24
references.pmid: 16832816
references.citation: Blood. 2008 May 1;111(9):4681-9
references.pmid: 18227347
references.citation: Hematology Am Soc Hematol Educ Program. 2011;2011:96-103
references.pmid: 22160019
references.citation: Ann Hematol. 2010 May;89(5):437-46
references.pmid: 20020127
references.citation: Nat Rev Cancer. 2010 Jan;10(1):37-50
references.pmid: 19956173
references.citation: Immunol Rev. 2012 Mar;246(1):379-400
references.pmid: 22435567
references.citation: PLoS One. 2008 Jul 02;3(7):e2555
references.pmid: 18596915
references.citation: J Clin Invest. 2012 Oct;122(10):3432-8
references.pmid: 23023714
references.citation: Blood. 2009 Nov 12;114(20):4441-50
references.pmid: 19762485
references.citation: J Cell Physiol. 2009 Sep;220(3):593-9
references.pmid: 19373868
references.citation: EMBO J. 2003 Jan 2;22(1):121-30
references.pmid: 12505990
references.citation: Blood. 2009 Jan 1;113(1):149-53
references.pmid: 18836097
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:77-81
references.pmid: 21239774
references.citation: Blood. 2007 Oct 1;110(7):2381-9
references.pmid: 17620454
references.citation: Leukemia. 2001 Nov;15(11):1721-8
references.pmid: 11681413
references.citation: J Immunol. 2000 Feb 15;164(4):2200-6
references.pmid: 10657675